|Dr. Steven C. Quay FCAP, M.D., Ph.D.||Chairman, CEO & Pres||1.18M||N/A||1951|
|Mr. Kyle Guse CPA, Esq., CPA||CFO, Gen. Counsel & Sec.||693.62k||N/A||1964|
|Ms. Heather Rees||VP of Fin. & Accounting||N/A||N/A||N/A|
|Ms. Delly Behen P.H.R.||VP of Admin. & HR||N/A||N/A||N/A|
|Mr. Charles Butler||VP of Investor & PR||N/A||N/A||N/A|
|Ms. Janet Rose Rea MSPH, RAC||Sr. VP of Regulatory, Quality & Clinical Affairs||N/A||N/A||N/A|
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Atossa Therapeutics, Inc.’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 10; Compensation: 8.